Structure Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Structure Therapeutics Inc. (GPCR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $731.00K.
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $4.19M.
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $4.92M.
- Structure Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $5.51M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $731.00K derived: sum of 3 quarters · filed 2026-08-06 | $4.92M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $731.00K derived: sum of 2 quarters · filed 2026-08-06 | $4.92M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $731.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.92M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $4.19M 10-Q · filed 2026-05-07 | |||
| 2023-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.51M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $3.83M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |